参考文献/References:
[1] 中华医学会内分泌学分会,中华医学会外科学分会内分泌学组,中国抗癌协会头颈肿瘤专业委员会,等.甲状腺结节和分化型甲状腺癌诊治指南[J].中华内分泌代谢杂志,2012,28(10):779-797.
[2] Molinaro E, Viola D, Passannanti P, et al. Recombinant human TSH(rhTSH) in 2009:new perspectives in diagnosis and therapy[J]. Q J Nucl Med Mol Imaging, 2009, 53(5):490-502.
[3] Pacini F, Molinaro E, Castagna MG, et al. Ablation of thyroid residues with 30 mCi 131I:a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal[J]. J Clin Endocrinol Metab, 2002, 87(9):4063-4068.
[4] Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma:results of an inter-national, randomized, controlled study[J]. J Clin Endocrinol Metab, 2006, 91(3):926-932.
[5] Schlumberger M, Ricard M, De Pouvourville G, et al. How the availability of recombinant human TSH has changed the manage-ment of patients who have thyroid cancer[J]. Nat Clin Pract Endocrinol Metab, 2007, 3(9):641-650.
[6] Hinscheid H, Lassmann M, Luster M, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer:procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal[J]. J Nucl Med, 2006, 47(4):648-654.
[7] 关海霞,陆汉魁.重组人促甲状腺激素在甲状腺疾病诊治中的应用[J].中华核医学与分子影像杂志,2012,32(4):311-314.
[8] Tuttle RM, Brokhin M, Omry G, et al. Recombinant human TSH-as-sisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal[J]. J Nucl Med, 2008, 49(5):764-770.
[9] Zanotti-Fregonara P, Hindié E, Toubert ME, et al. What role for recombinant human TSH in the treatment of metastatic thyroid cancer?[J]. Eur J Nucl Med Mol Imaging, 2009, 36(6):883-885.
[10] Luster M, Lippi F, Jarzab B, et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma:a comprehensive review[J]. Endocr Relat Cancer, 2005, 12(1):49-64.
[11] Rosário PW, Borges MA, Purisch S. Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity[J]. J Nucl Med, 2008, 49(11):1776-1782.
[12] Frigo A, Dardano A, Danese E, et al. Chromosome translocation frequency after radioiodine thyroid remnant ablation:a comparison between recombinant human thyrotropin stimulation and prolonged levothyroxine withdrawal[J]. J Clin Endocrinol Metab, 2009, 94(9):3472-3476.
[13] Barbaro D, Boni G, Meucci G, et al. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer:effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation[J]. J Clin Endocrinol Metab, 2003, 88(9):4110-4115.
[14] Rosario PW, Mineiro FA, Lacerda RX, et al. Long-term follow-up of at least five years after recombinant human thyrotropin compared to levothyroxine withdrawal for thyroid remnant ablation with radioactive iodine[J]. Thyroid, 2012, 22(3):332-333.
[15] Barbaro D, Boni G, Meucci G, et al. Recombinant human thyroid-stimulating hormone is effective for radioiodine ablation of post-surgical thyroid remnants[J]. Nucl Med Commun, 2006, 27(8):627-632.
[16] Taieb D, Sebag F, Cherenko M, et al. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation(RRA)with recombinant human TSH(rhTSH):a randomized controlled study[J]. Clin Endocrinol(Oxf), 2009, 71(1):115-123.
[17] Molinaro E, Giani C, Agate L, et al. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity 131I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up[J]. J Clin Endocrinol Metab, 2013, 98(7):2693-970.
[18] Luster M, Clarke SE, Dietlein M, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer[J]. Eur J Nucl Med Mol Imaging, 2008, 35(10):1941-1959.
[19] American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2009, 19(11):1167-1214.
[20] 傅宏亮,杜学亮,顾振辉,等.腺叶切除不完全分化型甲状腺癌131I疗效观察[J].上海交通大学学报:医学版,2010,30(3):268-270.
[21] Bal CS, Kumar A, Pant GS. Radioiodine lobar ablation as an alter-native to completion thyroidectomy in patients with differentiated thyroid cancer[J]. Nucl Med Commun, 2003, 24(2):203-208.
[22] Pacini F, Castagna MG, Brilli L, et al. Thyroid cancer:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2012, 23 Suppl 7:S110-119.
[23] Bal CS, Kumar A, Chandra P, et al. A prospective clinical trial to assess the efficacy of radioiodine ablation as an alternative to completion thyroidectomy in patients with differentiated thyroid cancer undergoing sub-total thyroidectomy[J]. Acta Oncol, 2006, 45(8):1067-1072.
[24] Santra A, Bal S, Mahargan S, et al. Long-term outcome of lobar ablation versus completion thyroidectomy in differentiated thyroid cancer[J]. Nucl Med Commun, 2011, 32(1):52-58.
[25] Randolph GW, Daniels GH. Radioactive iodine lobe ablation as an alternative to completion thyroidectomy for follicular carcinoma of the thyroid[J]. Thyroid, 2002, 12(11):989-996.
[26] Giovanella L, Piccardo A, Paone G, et al. Thyroid lobe ablation with iodine-131 in patients with differentiated-thyroid carcinoma:a randomized comparison between 1.1 and 3.7 GBq activities[J]. Nucl Med Commun, 2013, 34(8):767-770.
[27] Barbesino G, Goldfarb M, Parangi S, et al. Thyroid lobe ablation with radioactive iodine as an alternative to completion thyroidecto-my after hemithyroidectomy in patients with follicular thyroid carcinoma:long-term follow-up[J]. Thyroid, 2012, 22(4):369-576.
[28] National Comprehensive Cancer Network. NCCN clinical practiceguidelines in oncology:thyroid carcinoma[EB/OL].[2013-06-06]. http://www.nccn.org/professionals/physician_gls/fguidelines.asp.
[29] Pacini F, Castagna MG, Brilli L, et al. Thyroid cancer:EMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oneol, 2010, 21(5):214-219.
[30] 董峰,周荫保.分化型甲状腺癌术后131I清甲效果的影响因素[J].国际放射医学核医学杂志,2010,34(1):27-31.
[31] Cheng W, Ma C, Fu H, et al. Low-or hgh-dse rdioiodine rmnant alation for dfferentiated tyroid crcinoma:a meta-analysis[J]. J Clin Endocrinol Metab, 2013, 98(4):1353-1360.
[32] Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer[J]. Am J Med, 1994, 97(5):418-428.
[33] Creutzig H. High or low dose radioiodine ablation of thyroid remnants?[J]. Eur J Nucl Med, 1987, 12(10):500-502.
[34] Johansen K, Woodhouse NJ, Odugbesan O. Comparison of 1073 MBq and 3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer[J]. J Nucl Med, 1991, 32(2):252-254.
[35] Bal C, Padhy AK, Jana S, et al. Prospective randomized clinical trial to evaluate the optimal dose of 131I for remnant ablation in patients with differentiated thyroid carcinoma[J]. Cancer, 1996, 77(12):2574-2580.
[36] Bal CS, Kumar A, Pant GS. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma:a randomized clinical trial in 509 patients[J]. J Clin Endocrinol Metab, 2004, 89(4):1666-1673.
[37] Mallick U, Harmer C, Yap B, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer[J]. N Engl J Med, 2012, 366(18):1674-1685.
[38] Schlumberger M, Catargi B, Borget I, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer[J]. N Engl J Med, 2012, 366(18):1663-1673.
[39] Maenpaa HO, Heikkonen J, Vaalavirta L, et al. Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for can-cer:a randomized study[J/OL]. PLoS One, 2008, 3(4):1885[2013-06-06]. http://www.ncbi.nlm.nih.gov/pubmed/18382668.
[40] Doi SA, Woodhouse N J, Thalib L, et al. Ablation of the thyroid remnant and 1-131 dose in differentiated thyroid cancer:a meta-analysis revisited[J]. Clin Med Res, 2007, 5(2):87-90.
[41] Fallahi B, Beiki D, Takavar A, et al. Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma:a large randomized clinical trial[J]. Nucl Med Commun, 2012, 33(3):275-282.
相似文献/References:
[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]李盼丽,宋少莉.碘难治性分化型甲状腺癌靶向药物治疗进展[J].国际放射医学核医学杂志,2016,40(3):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
Li Panli,Song Shaoli.Radioactive iodine refractory differentiated thyroid cancer targeted therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
[3]邓艳,张伟.125I-碘酞酸盐临床应用进展[J].国际放射医学核医学杂志,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
Deng Yan,Zhang Wei.125I-iothalamate clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
[4]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[5]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[6]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[7]陈立,陈跃.分化型甲状腺癌骨转移诊断及疗效评价的核素显像研究进展[J].国际放射医学核医学杂志,2016,40(6):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
Chen Li,Chen Yue.Diagnosis and evaluation of curative effect progress of radionuclide imaging methods in differentiated thyroid cancer of bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
[8]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[9]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[10]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[11]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[12]寇莹,刘建中,郝新忠,等.甲状腺癌131I治疗后全身扫描盆腔浓聚131I的临床分析[J].国际放射医学核医学杂志,2014,38(1):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
Kou Ying,Liu Jianzhong,Hao Xinzhong,et al.Analysis of pelvic 131I uptake after 131I whole body scan in patients with thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
[13]成钊汀,谭建.分化型甲状腺癌术后患者131I治疗的辐射剂量与防护[J].国际放射医学核医学杂志,2014,38(2):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
Cheng Zhaoting,Tan Jian.Radiation dose and protection of differentiated thyroid carcinoma postoperative patients with 131I treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
[14]李莉,晋建华,陆克义,等.131I去除分化型甲状腺癌术后残留甲状腺组织疗效的meta分析[J].国际放射医学核医学杂志,2014,38(3):152.[doi:10.3760/cma.j.issn.1673-4114.2014.03.003]
Li Li,Jin Jianhua,Lu Keyi,et al.A meta-analysis of efficacy of iodine-131 for post-thyroidectomy ablation of remnants in patients with differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):152.[doi:10.3760/cma.j.issn.1673-4114.2014.03.003]
[15]李永军,徐兆强,柳卫,等.分化型甲状腺癌术后131I治疗患者胸腺生理性摄取131I的临床研究[J].国际放射医学核医学杂志,2014,38(4):227.[doi:10.3760/cma.j.issn.1673-4114.2014.04.005]
Li Yongjun,Xu Zhaoqiang,Liu Wei,et al.Clinical research on physiological thymic uptake of 131I in post-operative patients with differentiated thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):227.[doi:10.3760/cma.j.issn.1673-4114.2014.04.005]
[16]张璐,詹维伟,张一帆.颈部超声在分化型甲状腺癌131I治疗中的应用进展[J].国际放射医学核医学杂志,2014,38(4):271.[doi:10.3760/cma.j.issn.1673-4114.2014.04.015]
Zhang Lu,Zhan Weiwei,Zhang Yifan.Application of neck ultrasonography in 131I radiotherapy of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):271.[doi:10.3760/cma.j.issn.1673-4114.2014.04.015]
[17]汤敏敏,刘建中,武志芳,等.分化型甲状腺癌患者131I治疗后体内残留放射性活度的评估[J].国际放射医学核医学杂志,2014,38(6):363.[doi:10.3760/cma.j.issn.1673-4114.2014.06.004]
Tang Min-min,Liu Jian-zhong,Wu Zhi-fang,et al.Estimation of residual activities in patients with differentiated thyroid cancer after administration of 131I for therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):363.[doi:10.3760/cma.j.issn.1673-4114.2014.06.004]
[18]侯莎莎,沈婕,秦岚.131I全身显像及血清甲状腺球蛋白测定在分化型甲状腺癌治疗随访中的作用[J].国际放射医学核医学杂志,2013,37(5):269.[doi:10.3760/cma.j.issn.1673-4114.2013.05.004]
HOU Sha-sha,SHEN Jie,QIN Lan.Significance of 131I whole body scan combined with serum thyroglobulin in the follow-up of differentiated hyroid cancer after thyroid ablation[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):269.[doi:10.3760/cma.j.issn.1673-4114.2013.05.004]
[19]易艳玲,石洪成,顾宇参,等.分化型甲状腺癌患者日尿排泄131I活度分数估算[J].国际放射医学核医学杂志,2010,34(4):226.[doi:10.3760/cma.j.issn.1673-4114.2010.04.010]
YI Yah-ling,SHI Hong-cheng,GU Yu-shen,et al.Estimation the daily urinary excretion 131I radioactivity of patients with differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(1):226.[doi:10.3760/cma.j.issn.1673-4114.2010.04.010]
[20]董峰,周荫保.分化型甲状腺癌术后131I清甲效果的影响因素[J].国际放射医学核医学杂志,2010,34(1):27.[doi:10.3760/cma.j.issn.1673-4114.2010.01.007]
DONG Feng,ZHOU Yin-bao.Influencing factors of radioiodine ablation of posts-urgical thyroid remnants in differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(1):27.[doi:10.3760/cma.j.issn.1673-4114.2010.01.007]